Thus, these data indicated that pharmacologic inhibition of Nfatc1 translocation from the cytoplasm into the nucleus through cyclosporine A treatment could exert a partial therapeutic effect on tnni3k splicing mutation-based cardiomyopathy. The gene discussed is TNNI3K; the disease is cardiomyopathy.